[HTML][HTML] Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Background & Aims Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
C Celsa, G Cabibbo, C Am Fulgenzi… - Journal of …, 2023 - europepmc.org
Immune-related liver injury (irLI) is commonly observed in patients with cancer treated with
immune checkpoint inhibitors (ICIs). We aimed to compare incidence, clinical characteristics …
immune checkpoint inhibitors (ICIs). We aimed to compare incidence, clinical characteristics …
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, CAM Fulgenzi… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Background & aims Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
[引用][C] Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, N Roehlen… - Journal of …, 2024 - freidok.uni-freiburg.de
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, C Fulgenzi, B Scheiner… - JOURNAL OF …, 2024 - iris.unipa.it
Background & aims: Immune-related liver injury (irLI) is commonly observed in patients
with cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
with cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, CAM Fulgenzi… - JOURNAL OF …, 2024 - flore.unifi.it
Background & aims: Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, C Am Fulgenzi… - JOURNAL OF …, 2023 - iris.hunimed.eu
Background&aims: Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare incidence …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare incidence …
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo… - Journal of …, 2024 - utsouthwestern.elsevierpure.com
Background & Aims: Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
[HTML][HTML] Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, CAM Fulgenzi… - Journal of …, 2024 - journal-of-hepatology.eu
Background & Aims Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
[PDF][PDF] Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo - Journal of Hepatology, 2024 - flore.unifi.it
Background & Aims: Immune-related liver injury (irLI) is commonly observed in patients with
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …
cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the …